Kenneth G-J Ooi, Denis Wakefield,Frank A Billson, Stephanie L Watson
To investigate topical Atorvastatin, a novelocular therapy, for patients with dry eye associatedwith blepharitis.
10 patients with symptoms and signs of dryeye and blepharitis were enrolled in a prospective pilotstudy of topical Atorvastatin therapy over 1 month.The primary outcome measure was corneal fluoresceinstaining.
Results: An improvement in corneal fluoresceinstaining ?1 by point from baseline to completion of thetrial at week four was found in 9 of 10 patients(p = 0.007) and ?3 points in 6 of 10 patients in the studyeye. Topical statin significantly improved the blepharitisscore (p = 0.011) and the tear film break-up time(p = 0.005). Subjective dry eye symptoms improved(p = 0.005). There were no adverse events.
Topical Atorvastatin is a potential safetherapy for patients with dry eye and blepharitis. Itmay also be of benefit in other dry eye syndromes.
COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED FOLLOWING A ?TREAT AND EXTEND? PROTOCOL: EFFICACY VARIABLES FROM THE PRE-SPECIFIED 12- MONTH INTERIM ANALYSIS OF THE RIVAL STUDY